Khiron Life Sciences Corp.
KHRNF · OTC
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.04 | 0.03 | -0.00 |
| FCF Yield | -27.51% | -11.01% | -6.91% | -16.86% |
| EV / EBITDA | -7.67 | -7.51 | -9.29 | -10.36 |
| Quality | ||||
| ROIC | -11.87% | -9.74% | -15.26% | -8.61% |
| Gross Margin | 48.83% | 52.60% | 32.20% | 32.19% |
| Cash Conversion Ratio | 1.46 | 0.91 | 0.52 | 0.26 |
| Growth | ||||
| Revenue 3-Year CAGR | 26.30% | 22.49% | 15.85% | 10.12% |
| Free Cash Flow Growth | -140.00% | 20.99% | 50.44% | -24.26% |
| Safety | ||||
| Net Debt / EBITDA | -0.22 | 1.38 | 0.51 | 2.26 |
| Interest Coverage | -37.02 | -96.12 | -31.12 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.18 | 0.22 | 0.33 | 0.26 |
| Cash Conversion Cycle | 275.33 | 208.44 | 175.55 | 259.11 |